📊 AGEN Key Takeaways
Is Agenus Inc. (AGEN) a Good Investment?
Agenus exhibits critical financial deterioration with severe liquidity crisis, negative stockholders' equity of -$271.1M indicating technical insolvency, and massive cash burn of -$77.2M annually. Despite modest revenue growth of 10.4%, the company is operationally unprofitable with -$20.2M operating loss and cannot sustain operations without external capital infusion.
Agenus shows modest revenue growth, but the quality of that growth is weak because it is paired with deeply negative operating margins and heavy cash burn. The near-breakeven net income appears unsupported by core operations, while negative equity, very low cash, and weak liquidity point to significant financial stress and a high dependence on external financing.
Why Buy Agenus Inc. Stock? AGEN Key Strengths
- Revenue growth of 10.4% YoY shows top-line expansion in biologics sector
- Modest improvement in net loss from prior year (-101.0K vs larger prior loss)
- Recent insider activity with 8 Form 4 filings suggests management engagement
- Revenue grew 10.4% year over year, indicating continued commercial or collaboration activity
- Net loss narrowed sharply versus the prior year, showing headline earnings improvement
- Capital expenditure requirements are minimal, which limits additional fixed investment burden
AGEN Stock Risks: Agenus Inc. Investment Risks
- Negative stockholders' equity of -$271.1M indicates technical insolvency and potential bankruptcy risk
- Severe liquidity crisis with current ratio of 0.41x and only $3.0M cash against $44.7M long-term debt
- Massive negative free cash flow of -$77.2M annually with -67.6% FCF margin unsustainable without funding
- Operating losses of -$20.2M despite revenue generation indicate fundamental business model problems
- Negative interest coverage of -0.6x shows inability to service debt from operations
- Liquidity is extremely weak, with only $3.0M in cash and a 0.41x current ratio
- Free cash flow and operating cash flow are deeply negative, indicating the business is not self-funding
- Negative stockholders equity and weak interest coverage reflect a stressed balance sheet and elevated financing risk
Key Metrics to Watch
- Cash and equivalents trend - critical for survival without dilutive capital raises
- Operating cash flow trajectory - must show material improvement toward positive territory
- Revenue growth sustainability - verify 10.4% growth continues amid cash constraints
- Debt refinancing activities - watch for distressed negotiations affecting capital structure
- Quarterly operating cash burn relative to cash on hand
- Revenue durability and whether operating income improves toward sustained profitability
Agenus Inc. (AGEN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
AGEN Profit Margin, ROE & Profitability Analysis
AGEN vs Healthcare Sector: How Agenus Inc. Compares
How Agenus Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Agenus Inc. Stock Overvalued? AGEN Valuation Analysis 2026
Based on fundamental analysis, Agenus Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Agenus Inc. Balance Sheet: AGEN Debt, Cash & Liquidity
AGEN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Agenus Inc.'s revenue has declined by 47% over the 5-year period, indicating business contraction. The most recent EPS of $-13.75 indicates the company is currently unprofitable.
AGEN Revenue Growth, EPS Growth & YoY Performance
AGEN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $25.1M | $7.5M | $0.37 |
| Q2 2025 | $23.5M | -$26.4M | $-1.00 |
| Q1 2025 | $24.1M | -$26.4M | $-1.03 |
| Q3 2024 | $24.3M | -$54.8M | $-3.08 |
| Q2 2024 | $23.5M | -$54.8M | $-2.52 |
| Q1 2024 | $22.9M | -$63.5M | $-3.04 |
| Q3 2023 | $22.8M | -$49.2M | $-0.16 |
| Q2 2023 | $20.9M | -$49.2M | $-0.17 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Agenus Inc. Dividends, Buybacks & Capital Allocation
AGEN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Agenus Inc. (CIK: 0001098972)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AGEN
What is the AI rating for AGEN?
Agenus Inc. (AGEN) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AGEN's key strengths?
Claude: Revenue growth of 10.4% YoY shows top-line expansion in biologics sector. Modest improvement in net loss from prior year (-101.0K vs larger prior loss). ChatGPT: Revenue grew 10.4% year over year, indicating continued commercial or collaboration activity. Net loss narrowed sharply versus the prior year, showing headline earnings improvement.
What are the risks of investing in AGEN?
Claude: Negative stockholders' equity of -$271.1M indicates technical insolvency and potential bankruptcy risk. Severe liquidity crisis with current ratio of 0.41x and only $3.0M cash against $44.7M long-term debt. ChatGPT: Liquidity is extremely weak, with only $3.0M in cash and a 0.41x current ratio. Free cash flow and operating cash flow are deeply negative, indicating the business is not self-funding.
What is AGEN's revenue and growth?
Agenus Inc. reported revenue of $114.2M.
Does AGEN pay dividends?
Agenus Inc. does not currently pay dividends.
Where can I find AGEN SEC filings?
Official SEC filings for Agenus Inc. (CIK: 0001098972) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AGEN's EPS?
Agenus Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AGEN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Agenus Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AGEN stock overvalued or undervalued?
Valuation metrics for AGEN: ROE of N/A (sector avg: 15%), net margin of -0.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AGEN stock in 2026?
Our dual AI analysis gives Agenus Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AGEN's free cash flow?
Agenus Inc.'s operating cash flow is $-77.2M, with capital expenditures of $6.0K. FCF margin is -67.6%.
How does AGEN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -0.1% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.41 (avg: 2).